Steroid Regimen for Inflammatory Bowel Disease
For moderate to severe IBD, start prednisolone 40 mg daily and taper gradually over 8 weeks; more rapid reduction increases early relapse risk. 1
Steroid Dosing by Disease Severity and Location
Crohn's Disease
Mild to Moderate Ileocolonic Disease:
- Start with high-dose mesalazine (4 g/daily) as initial therapy 1
- If inadequate response, escalate to prednisolone 40 mg daily 1
Isolated Ileo-caecal Disease:
- Budesonide 9 mg daily is appropriate but marginally less effective than prednisolone 1
- Consider this for patients wanting to minimize systemic steroid effects
Severe Disease:
- Intravenous hydrocortisone 400 mg/day OR methylprednisolone 60 mg/day 1
- Add concomitant IV metronidazole to distinguish active disease from septic complications 1
Ulcerative Colitis
Moderate to Severe Disease:
- Prednisolone 40 mg daily combined with 5-ASA 2
- If no response to high-dose 5-ASA alone within 2 weeks, initiate corticosteroids 2
Severe Colitis:
- Intravenous steroids (same dosing as severe CD) 1
- Joint management with gastroenterologist and colorectal surgeon 1
Critical Tapering Protocol
The 8-week taper is essential - prednisolone should be reduced gradually according to severity and patient response over 8 weeks. More rapid reduction is associated with early relapse 1. Recent quality improvement data suggests median steroid duration can be reduced to approximately 50 days when combined with anti-TNF therapy and rigorous weekly monitoring 3.
Rapid tapering option: Consider 10 mg/week reduction where possible, balanced against risks of extending overall steroid exposure 4. This must be carefully monitored.
Alternative steroids for UC flares:
- Budesonide MMX 9 mg/day for 8 weeks 4
- Beclometasone 5 mg/day for 4 weeks 4
- Assess response after 2 weeks 4
Critical Pitfalls
Steroids should be avoided if possible - they are an established risk factor for respiratory tract infection, opportunistic infection, and septicemia in IBD 4. Patients on prednisolone ≥20 mg daily should observe "shielding" precautions 4.
Never use steroids for maintenance therapy - they are not recommended for long-term maintenance despite their effectiveness for induction 2. Long-term steroid use is undesirable and steroid-sparing has become a critical therapeutic goal 5.
Biologic Therapy Approach
Infliximab 5 mg/kg is effective for active Crohn's disease but should be reserved for patients who have failed medical therapy or used as part of a comprehensive strategy including immunomodulation. 1
When to Initiate Biologics
Start advanced therapy (biologics/small molecules) if: 2
- No adequate response to oral corticosteroids within 2 weeks
- Unsuccessful corticosteroid taper
- Need to avoid repeated courses of corticosteroids
For fistulating Crohn's disease:
- Infliximab (three infusions of 5 mg/kg at 0,2, and 6 weeks) should be reserved for perianal or enterocutaneous fistulae refractory to other treatment 1
- Must be used as part of a strategy that includes immunomodulation and surgery 1
- Avoid in patients with obstructive symptoms 1
First-Line Biologic Selection
For Ulcerative Colitis: The most recent high-quality real-world evidence demonstrates vedolizumab is superior to anti-TNF agents as first-line therapy for achieving clinical remission, steroid-free clinical remission, and steroid-free deep remission 6. This finding is consistent across multiple data sources including the VARSITY trial and real-world cohorts 7.
For Crohn's Disease:
- Infliximab shows superior effectiveness compared to adalimumab, particularly in perianal disease 6
- Consider adalimumab for monotherapy to promote home care and lower immunogenicity risk relative to infliximab 4
Biologic Sequencing After First-Line Failure
After anti-TNF failure:
For Ulcerative Colitis:
- Switch to vedolizumab, ustekinumab, tofacitinib, or upadacitinib - these maintain efficacy after anti-TNF failure 8
- Avoid switching to a second anti-TNF - vedolizumab was superior to second anti-TNF after first anti-TNF failure 6
- Adalimumab, vedolizumab, and ozanimod show lower clinical remission rates after prior anti-TNF therapy 8
- Ustekinumab, tofacitinib, and upadacitinib maintain efficacy regardless of prior anti-TNF exposure 8
For Crohn's Disease:
- Non-anti-TNF biologics are superior to a second anti-TNF after first-line anti-TNF failure 6
- Ustekinumab and risankizumab maintain endoscopic remission rates after prior anti-TNF therapy 8
- Adalimumab and vedolizumab show persistently lower endoscopic remission rates after prior anti-TNF 8
After vedolizumab failure:
- Anti-TNF effectiveness is not significantly impacted by prior vedolizumab therapy 8
- This suggests potential benefit of using vedolizumab as first-line, preserving anti-TNF options 8
Key principle: Patients experiencing TNF failure due to delayed loss of response or intolerance have superior outcomes switching to a non-anti-TNF biologic rather than a second anti-TNF 6.
Combination Therapy Considerations
Azathioprine 1.5-2.5 mg/kg/day or mercaptopurine 0.75-1.5 mg/kg/day:
- Can be used as adjunctive therapy and steroid-sparing agent 1
- Slow onset of action precludes use as sole therapy 1
- Suggested alongside infliximab therapy for maintenance 2
- Combination therapy decisions should be made case-by-case with careful risk-benefit discussion 4
During COVID-19 or high-risk periods:
- Consider monotherapy initiation rather than combination therapy 4
- Older patients (>60 years) in sustained remission on thiopurines may consider stopping after discussion 4
Monitoring and Optimization
If incomplete clinical response:
- Increase dose or decrease interval of biologic administration 9
- Use early therapeutic drug monitoring to identify patients appropriate for later combination immunosuppression 4
Primary failure:
- Switch to another biologic class rather than another agent in the same class 9
Treatment goal: Clinical remission with mucosal healing, not just clinical response 9. The overall treatment goal has shifted to achieving remission assessed biochemically, endoscopically, and histologically 2.